The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) today approved the proposal of the Executive Board and Supervisory Board, resolving to pay a dividend of EUR 0.22 per share for the 2025 fiscal year, a significant increase from EUR 0.17 per share in the previous year. The in-person meeting, held near the company's headquarters in Berlin, saw representation of 55.37% of the company's share capital. Shareholders endorsed the actions of the Executive Board and Supervisory Board for the 2025 fiscal year and approved all agenda items by a large majority.
The dividend increase signals confidence in the company's financial health and future prospects. Eckert & Ziegler SE is a leading specialist in isotope-related components for nuclear medicine and radiation therapy, employing over 1,000 people. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development to contract manufacturing and distribution. Its shares are listed in the TecDAX index of Deutsche Börse.
The detailed voting results and the CEO's presentation are available on the company's website. The approval of a higher dividend reflects the company's strong operational performance and its commitment to returning value to shareholders. This development is important for investors as it underscores the company's stable cash flow generation and its ability to reward shareholders while continuing to invest in growth.
The dividend increase also highlights the company's resilience in the nuclear medicine and radiation therapy sectors, which are critical for healthcare. Eckert & Ziegler SE's role as a key supplier in these fields positions it well for sustained demand. The approval of the dividend and the high shareholder representation indicate strong support for the company's strategic direction.
Overall, the Annual General Meeting's decision to raise the dividend is a positive signal for the market, reflecting Eckert & Ziegler SE's solid financial footing and its focus on shareholder value. The company continues to contribute to saving lives through its innovative products and services in nuclear medicine and radiation therapy.
